Survival rate of patients with bladder cancer in Yazd, central province of Iran

Abstract Background: Bladder cancer is the ninth most commonly diagnosed malignancy worldwide. The trend of bladder cancer incidence and mortality is rising in Iran. This study was aimed to evaluate the survival rate of patients with bladder cancer in Yazd province, Iran. Methods: In this retrospective cohort study, data were collected from 340 patients suffering from bladder cancer referred to Shahid Rahnemon and Shohada-Kargar Hospitals in Yazd province, Iran between April, 2001 and March, 2012. Variables included age, gender, stage of cancer, place of residence and type of treatment. The Kaplan-Meier and Cox regression analyses were used to evaluate the relationship between each variable and survival time. A P value less than 0.05 was considered significant. Results: The mean age of total patients was 65.8 ± 13.6 years, and their mean survival time was 68.55 ± 6.05 months. Cumulative survival rates at the end of 1, 3, and 5 years in bladder cancer patients were 91%, 58%, and 51.4%, respectively. A statistically significant association was found between age (P = 0.005), stage of disease (P = 0.0003), type of treatment (P = 0.0003) and survival time of patients. Data showed no significant correlation between age, gender, place of residence and patients’ survival. Conclusions: The survival of patients suffering from bladder cancer in this study was less than other reports. Patients’age and cancer stage were the effective factors in survival time. Continuous screening of older people for cancer diagnosis in early stages is seemed to improve survival in patients. Keywords: Bladder; Cancer; Survival Rate; Ira

Evaluation of Cholecystectomy complications in diabetic and non-diabetic patients in Kerman university hospitals from the year 1374 to 1377

Abstract: Diabetes mellitus is a systemic disease that involves multiple organs. Several documented studies indicated that prevalence of gallstone in diabetics is higher than nondiabetics. Thus, rate of acute cholecystitis and cholecystectomy should be higher in these patients. Some studies have shown that the risk of postoperative complications is higher in the diabetics. This cross-sectional study has been done from 1374 to 1377 in two university hospitals (Bahonar and Kerman-Darman) of Kerman. The study is conducted on 227 sequential patients with cholecystitis that were candidates for cholecystectomy within 72 hours of diagnosis. After preliminary therapy and Para clinic study, including fasting blood sugar (FBS) measurement, upper midline laparotomy was performed-following induction of general balanced anesthesia. Stage of the disease was registered during the operation. The subjects were followed up to 30 days for detection of postoperative complications. There were 34 (15%) diabetics (5 type-1 and 28 type-2 diabetics) with age of 62.6±11.9 years, and 193 (85%) nondiabetic patients aged 54.4±15.8 years old. Therefore the age of diabetics were higher than that of nondiabetics (P=0.0008). FBS of diabetic and nondiabetic groups were 189.12±53.64 mg/dl and 91.44±15.15 mg/dl respectively (P=0.0001). As for as progression of the disease, 25 (23.5%) of diabetics and 90 (74%)of non diabetics had a higher stages of cholecystitis (P<0.05). Postoperative complications were encountered in 15 (38.4%) cases of diabetic and 21 (10.5%) cases of nondiabetic groups (P<0.001, OR=5.33, X²=19.86). It seems that increased prevalence of postoperative complications in diabetic patients is due to more advanced stages of their disease at the time of diagnosis. However systemic changes due to aging in diabetic patients should also be considered. Keywords: Acute cholecystitis, Diabetes mellitus, Operative complicatio

A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere� (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy

Background: Docetaxel is a clinically well established antimitotic chemotherapy medication. Labeled docetaxel indications are breast cancer, gastric cancer, head and neck cancer, non�small cell lung cancer, and prostate cancer. Objective: This is a Phase IV study to evaluate the safety profile of docetaxel (Alvotere; NanoAlvand, Iran) in Iranian patients diagnosed with different types of cancers receiving chemotherapy regimens with docetaxel. Methods: Patients who received Alvotere as a part of their chemotherapy regimen were enrolled in this Phase IV, observational, multicenter, open-label study. Alvotere was administrated as a single agent or in combination with other chemotherapy agents. Safety parameters in each cycle were assessed, and the related data were recorded in booklets. Findings: A total of 411 patients with different types of cancers were enrolled from 25 centers in Iran. The most common malignancies among participants were breast cancer (49.88), followed by gastric cancer (22.63). Participants� mean age was 53.33 years, and the mean total dose used in each cycle was 132 mg. According to the results, 341 patients experienced at least 1 adverse event, that the most common was alopecia (41.12). In total, 92 (22.38) patients had at least 1 adverse event of grade 3 or 4, and 25 (6.08) patients showed 54 serious adverse events, which the causality assessment for all was possibly related to Alvotere. There was a significant difference between men and women in the incidence of skin and subcutaneous tissue disorders (55.63 in women vs 41.73 in men; P = 0.009). Also, the incidence of gastrointestinal disorders, nervous system disorders, skin and subcutaneous tissue disorders, hepatic enzymes increase, and fluid retention was significantly higher (P < 0.05) in patients receiving anthracyclines in their chemotherapy regimens. Conclusions: The findings of this open-label, observational, multicenter, postmarketing surveillance showed that Alvotere appears to have an acceptable safety profile in Iranian cancer patients receiving chemotherapeutic regimens. (Curr Ther Res Clin Exp. 2022; 82:XXX�XXX) © 2022 Elsevier HS Journals, Inc. © 202